Literature DB >> 12497083

The immunotherapy of prostate cancer.

A G Dalgleish1, M J A Perry, J D Eaton, D Hrouda, S M Todryk, R S Kirby.   

Abstract

Advanced prostate cancer remains incurable with standard treatment options. Immunotherapy may be a realistic alternative given the growing evidence that the immune response can affect the growth of other solid tumours and the regulation of both specific and shared prostate cancer antigens. Early studies suggest that both non-specific and specific vaccines can effect relevant animal models and clinical trials based on these observations are now in progress. A number of other approaches including gene therapy with HSVtk are already undergoing clinical studies (Herman et al. Hum Gene Ther 1999; 10: 1239-1249). Prostate Cancer and Prostatic Diseases (2000) 3, 303-307

Entities:  

Year:  2000        PMID: 12497083     DOI: 10.1038/sj.pcan.4500487

Source DB:  PubMed          Journal:  Prostate Cancer Prostatic Dis        ISSN: 1365-7852            Impact factor:   5.554


  1 in total

1.  Correlation between HLA-A2 gene frequency, latitude, ovarian and prostate cancer mortality rates.

Authors:  Luigi De Petris; Kjell Bergfeldt; Christina Hising; Andreas Lundqvist; Bengt Tholander; Pavel Pisa; Henk G M van der Zanden; Giuseppe Masucci
Journal:  Med Oncol       Date:  2004       Impact factor: 3.064

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.